CKD Mineral and Bone Disease — Medical Education Handout

Overview

CKD mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral metabolism unique to kidney disease. It encompasses dysregulation of phosphate, calcium, fibroblast growth factor-23 (FGF-23), parathyroid hormone (PTH), and vitamin D, resulting in abnormalities of bone architecture (renal osteodystrophy), vascular calcification, and systemic mineral imbalance. CKD-MBD significantly contributes to cardiovascular mortality and morbidity in CKD and ESRD populations.

High-Yield Board Point

CKD-MBD pathophysiology centers on phosphate retention: eGFR decline → reduced phosphate excretion → serum phosphate elevation → FGF-23 rise → secondary PTH elevation → vitamin D suppression. Hyperparathyroidism drives bone loss and vascular calcification. KDIGO targets: keep Ca/P within normal, target PTH to 2–9× normal for stage (varies by KDIGO stage), minimize vascular calcification.

Pathophysiology: The Cascade

Phase 1: Early CKD (G3a–G3b, eGFR 30–59)

Phosphate Retention

eGFR decline → reduced filtered phosphate load → serum phosphate rises (mild, ~3.5–4.5)
Phosphate rise stimulates FGF-23 production (by osteocytes)

FGF-23 Elevation

FGF-23 acts via FGF receptor + Klotho (Klotho is a co-factor; highly expressed in kidney and parathyroid)
FGF-23 increases phosphate excretion (tubular)
FGF-23 suppresses 1,25-dihydroxyvitamin D [1,25(OH)₂D] production (downregulates 1-alpha hydroxylase)
FGF-23 directly suppresses PTH secretion (early phase)

Vitamin D Decline

Reduced 1,25(OH)₂D production → reduced calcium reabsorption in intestine
Hypocalcemia develops (mild, often <8.5 mg/dL)

Phase 2: Progressive CKD (G4, eGFR 15–29)

Phosphate Accumulation

Serum phosphate rises further (>4.5 mg/dL)
Hyperphosphatemia directly stimulates PTH secretion

Secondary Hyperparathyroidism (SHPT) Develops

Hypocalcemia + hyperphosphatemia + low 1,25(OH)₂D → PTH secretion rises
Parathyroid gland hyperplasia develops (chronic stimulation)
PTH rises disproportionately; negative feedback loop broken

PTH Effects

Increased bone resorption (osteoclast activation)
Increased 1,25(OH)₂D production (via 1-alpha hydroxylase in residual renal tubules)
Increased phosphate excretion (but diminishing effect with declining GFR)

Phase 3: ESRD (G5, eGFR <15)

Severe Dysregulation

Serum phosphate >5.0 mg/dL (often 6–8)
PTH severely elevated (often >500–1000 pg/mL if untreated)
Calcium may be normal or elevated (from PTH-driven mobilization + loss of Klotho signaling)
FGF-23 extreme elevation (>1000 pg/mL)

Consequences

Bone: Severe renal osteodystrophy; pathologic fractures
Vascular: Extensive calcification of coronary arteries, arterial walls, soft tissues
Systemic: Hyperkalemia, metabolic acidosis, anemia (from EPO resistance + PTH suppression), cardiac arrhythmias

Types of Renal Osteodystrophy (ROD)

Kidney biopsy and bone biomarkers (PTH, alkaline phosphatase, P1NP) classify renal bone disease.

High Bone Turnover Disease (Osteitis Fibrosa)

Pathology	Increased osteoblast and osteoclast activity; peritrabecular fibrosis
Biomarkers	PTH >300 pg/mL (typically), high alkaline phosphatase, elevated P1NP
Prevalence	~70–80% of ESRD patients on dialysis
Pathophysiology	SHPT → excessive PTH → bone resorption outpaces formation
Clinical Features	Bone pain, proximal weakness, high fracture risk despite high turnover (paradox: increased turnover but poor bone quality)
Management	Target phosphate, normalize calcium, PTH suppression with vitamin D ± calcimimetics

Adynamic Bone Disease

Pathology	Low bone cell activity; minimal osteoblast/osteoclast function; replacement of bone with woven fibrous tissue
Biomarkers	PTH <150 pg/mL (classically), low-normal alkaline phosphatase, low P1NP
Prevalence	~20–30% of ESRD; increasing due to aggressive PTH suppression
Pathophysiology	Excessive suppression of PTH (over-treatment with vitamin D/calcimimetics); accumulation of aluminum or strontium
Risk Factors	Chronic aluminum exposure (contaminated dialysate, binders), over-aggressive PTH suppression, older age, diabetes
Clinical Features	Fracture risk paradoxically high (poor bone formation despite low resorption); slow healing
Management	Moderate PTH suppression (target 2–9× normal); avoid excessive vitamin D; remove aluminum; minimize calcimimetics if possible

Osteomalacia

Pathology	Defective mineralization; accumulation of unmineralized osteoid
Biomarkers	Low PTH, elevated alkaline phosphatase, elevated osteoid volume on biopsy
Pathophysiology	Severe vitamin D deficiency (decreased 1,25(OH)₂D); aluminum deposition in bone
Clinical Features	Bone pain, muscle weakness, fractures
Management	Vitamin D (native or active form); treat aluminum exposure

Mixed Uremic Osteodystrophy

Pathology	Features of both high turnover and low turnover disease; heterogeneous bone changes
Biomarkers	Intermediate PTH, variable alkaline phosphatase
Prevalence	~5–10% of ESRD
Management	Balance PTH suppression; optimize phosphate and calcium; vitamin D supplementation

Clinical Pearl

The classic teaching—“high PTH = high turnover, low PTH = low turnover”—is helpful but incomplete. Adynamic bone disease can develop despite PTH suppression if aluminum accumulates or if vitamin D is withheld. Always treat to KDIGO targets and monitor bone marker trends.

Vascular Calcification in CKD-MBD

Pathophysiology

Hyperphosphatemia and elevation of the calcium-phosphate product (Ca × P) drive vascular smooth muscle cell phenotypic transition to osteogenic cells, resulting in calcification. Unlike atherosclerotic calcification (intimal), uremic calcification is predominantly medial (vascular wall) and is mediated by loss of natural inhibitors (fetuin-A, pyrophosphate).

Clinical Consequences

Arterial stiffness → increased pulse pressure → LVH → diastolic dysfunction
Coronary artery calcification → accelerated CAD; increased MI risk
Medial sclerosis → reduced arterial compliance; poor coronary perfusion
Valvular calcification → aortic/mitral disease
Soft tissue calcification → calciphylaxis (rare but life-threatening); metastatic calcification

Mortality Impact

Coronary artery calcification score independently predicts cardiovascular death in CKD and ESRD populations.

KDIGO 2017 CKD-MBD Targets by Stage

Stage	eGFR	PTH	Phosphate	Calcium	Notes
G3a	45–59	Normal × 1–1.5×	Normal	Normal	Avoid chronic hypercalcemia; prevent hyperphosphatemia
G3b	30–44	Normal × 1.5×	Monitor; restrict if elevated	Monitor	Early intervention: restrict phosphate diet, consider binders
G4	15–29	Normal × 1.5–3×	Aim <4.6 mg/dL	8.5–10 mg/dL	Restrict phosphate; start vitamin D if deficient; assess for hyperparathyroidism
G5D	<15	Normal × 2–9×	3.5–5.5 mg/dL	8.5–10 mg/dL	Intensive management: multiple modalities; individualize targets

Key Point

Avoid rapid, aggressive changes in mineral parameters. Overcorrection (excessive PTH suppression, hypercalcemia) risks adynamic bone disease and calcification. The goal is gradual normalization of phosphate and calcium, with PTH maintained in a physiologic range.

Management Strategy

Phosphate Management

Dietary Restriction

Target: <1000–1200 mg/day (vs. normal 1000–1500 mg/day)
Education: Limit dairy, processed meats, nuts, whole grains
Challenge: Palatability and adherence in advanced CKD

Phosphate Binders

Used when dietary restriction alone is inadequate (typically when serum P >4.5 mg/dL in G4–G5).

Binder Class	Agent	Mechanism	Advantages	Disadvantages
Calcium-based	Calcium carbonate, calcium acetate	Binds PO₄ in gut; increases Ca absorption	Inexpensive; improves Ca balance	Risk of hypercalcemia; promotes vascular calcification if used excessively
Non-calcium	Sevelamer HCl, sevelamer carbonate	Polymer binds phosphate	No hypercalcemia risk; may lower cholesterol	GI side effects; large pill burden
Lanthanum carbonate	Lanthanum	Rare earth binds phosphate	Effective; reasonable pill burden	Minimal long-term safety data; rare GI toxicity
Iron-based	Sucroferric oxyhydroxide, ferric citrate	Iron core binds phosphate	Effective; may improve iron status (ferric citrate)	GI upset possible; dark stool
Magnesium-based	Magnesium carbonate	Magnesium + carbonate binds phosphate	Avoids Ca/Al excess	Hypermagnesemia risk (usually offset by dialysis)

KDIGO 2017 Recommendation

“Restrict dose of calcium-based binders; calcium-free binders may favor halting progression of vascular calcification compared with calcium-containing binders.”

Practical Approach

G3b–G4: Start dietary restriction; add binder only if persistent hyperphosphatemia
G5D: Use combination therapy (non-calcium binder + smaller dose calcium binder, or non-calcium monotherapy)

Vitamin D Supplementation

Type	Agent	Indication	Advantages	Disadvantages
Native	Cholecalciferol (D3)	CKD G3–G4 with low 25(OH)D	Safe; physiologic; inexpensive	Slow onset; may not be adequate in G4 with very low 1,25(OH)₂D
Active	Calcitriol, paricalcitol, doxercalciferol	CKD G4–G5D with SHPT	Rapid PTH suppression; improves Ca/P balance	Risk of hypercalcemia; need monitoring; expensive
Calcimimetic	Cinacalcet, etelcalcetide	SHPT refractory to vitamin D	Suppress PTH directly; no hypercalcemia risk; may reduce need for parathyroidectomy	Nausea, vomiting; risk of hypocalcemia; expensive

KDIGO Recommendations

CKD G3–G4 with vitamin D deficiency: Treat with native vitamin D if 25(OH)D <30 ng/mL
CKD G5D with PTH >150 pg/mL despite phosphate/calcium control: Consider active vitamin D (calcitriol, paricalcitol) ± calcimimetic
Avoid: Chronic hypercalcemia (≥10.5 mg/dL); target calcium 8.5–10.0 mg/dL

Parathyroidectomy Indications

When to Refer to Surgery

SHPT refractory to medical management: PTH >800 pg/mL, hypercalcemia (despite binders, vitamin D, calcimimetics), symptomatic (bone pain, fractures)
Non-adherence to dialysis/therapy: Patient unable/unwilling to take medications
Duration: Usually after 6–12 months of failed medical management
Post-transplant: Tertiary SHPT with persistent hypercalcemia + hyperparathyroidism
Surgical approaches: Subtotal parathyroidectomy or total with autotransplant

Post-Operative Warning: Hungry Bone Syndrome

Post-parathyroidectomy, monitor Cr, calcium, phosphate. Administer IV calcium + dextrose to prevent “hungry bone syndrome” (acute hypocalcemia from rapid bone healing).

Bone Biopsy and Biomarkers

When to Biopsy

Not routinely recommended; consider if:

Unexplained fractures or bone pain despite normal biochemistry
Severe hypercalcemia with suppressed PTH (suspect adynamic bone disease or aluminum)
Before parathyroidectomy decision (to assess bone turnover)

Non-Invasive Biomarkers

Marker	Interpretation	Use
PTH (intact)	High → high turnover; low → low turnover	Primary screening; KDIGO targets
Alkaline phosphatase (ALP)	Elevated with high turnover; normal/low with low turnover	Adjunctive; supports PTH findings
Bone-specific ALP	More specific for bone than total ALP	Less used; when available, specific for bone turnover
P1NP	Marker of bone formation; high in high turnover	Research; emerging use in clinical practice
CTX	Marker of bone resorption	Less used in CKD; more in osteoporosis research
FGF-23	Markedly elevated in CKD; reflects phosphate burden	Research marker; not routinely ordered; prognostic for CV events